Cantor Fitzgerald’s Maravai LifeSciences MRVI Stock Holding History

Cantor Fitzgerald’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-112,750	Closed	-$1.13M	–	439
2023 Q3	$1.13M	Buy	112,750 +46,750	+71%	+$513K	0.03%	260
2023 Q2	$820K	Buy	+66,000	New	+$891K	0.02%	325
2022 Q3	–	Sell	-10,001	Closed	-$284K	–	824
2022 Q2	$284K	Sell	10,001 -81,000	-89%	-$2.57M	0.01%	615
2022 Q1	$3.21M	Buy	+91,001	New	+$3.05M	0.24%	108

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Cantor Fitzgerald's MRVI Position: Q4 2023 in Review

Cantor Fitzgerald sold out of Maravai LifeSciences (MRVI) in Q4 2023, closing a stake of 112,750 shares — an estimated $1.13M sold.

Cantor Fitzgerald first reported a position in MRVI in Q1 2022 and held it in 4 quarters. The position peaked at $3.21M in Q1 2022. 223 funds tracked by Wall St. Rank hold MRVI as of Q4 2023.

Cantor Fitzgerald reported no remaining Maravai LifeSciences position as of Q4 2023 after selling out during the quarter.
Cantor Fitzgerald sold 112,750 Maravai LifeSciences shares in Q4 2023, an estimated $1.13M.
Cantor Fitzgerald first reported a position in Maravai LifeSciences in Q1 2022 and held it in 4 quarters.
Cantor Fitzgerald's Maravai LifeSciences position peaked at $3.21M in Q1 2022.
223 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2023.

Based on Cantor Fitzgerald's 13F filing for Q4 2023, filed 14 Feb 2024.